Innovative Clinical Trials for Canine and Feline Health
TACC invites our referring partners to refer eligible patients for two exciting clinical trials that aim to advance the health and well-being of companion animals.
The TRIAD Study: Promoting Healthy Aging in Dogs
The TRIAD study is designed to test whether rapamycin can improve healthy aging in companion dogs. We are seeking older dogs, aged 7 years or older and weighing between 44 - 120 pounds, to participate in this clinical trial. The Test of Rapamycin In Aging Dogs (TRIAD) is a double-blind, placebo-controlled clinical trial of the mTOR inhibitor rapamycin, which at low doses has been shown to increase lifespan and delay or reverse many age-related disorders in mice. This is the third and largest trial of rapamycin that our group has conducted to date. What is its purpose? The goal of TRIAD is to assess the effects of the medication Rapamycin on health and aging in dogs. This study is designed to test if Rapamycin treatment leads to any of the following benefits: Better Heart Health, Improved Mobility, Prolonged Cognitive Function, Increased Lifespan
The TRIAD study is designed to test whether rapamycin can improve healthy aging in companion dogs. We are seeking older dogs, aged 7 years or older and weighing between 44 - 120 pounds, to participate in this clinical trial. The Test of Rapamycin In Aging Dogs (TRIAD) is a double-blind, placebo-controlled clinical trial of the mTOR inhibitor rapamycin, which at low doses has been shown to increase lifespan and delay or reverse many age-related disorders in mice. This is the third and largest trial of rapamycin that our group has conducted to date. What is its purpose? The goal of TRIAD is to assess the effects of the medication Rapamycin on health and aging in dogs. This study is designed to test if Rapamycin treatment leads to any of the following benefits: Better Heart Health, Improved Mobility, Prolonged Cognitive Function, Increased Lifespan
The HALT HCM Study: Addressing Hypertrophic Cardiomyopathy in Cats
The HALT study is a multi-site, blinded, randomized, placebo-controlled clinical field study to provide substantial evidence of effectiveness of a disease modifying drug intervention in the management of ventricular hypertrophy in cats with subclinical HCM. The study will be conducted at multiple clinical sites that are experienced in treating cats with HCM. The study will consist of up to a 14-dayscreening period, followed by a 12-month once-weekly dosing period, with five post-enrollment study visits.
How to Refer a Patient to the HALT Study:
Click below to visit HCMincats.com
Select the investigation site most local to you
Select the veterinarian form
Complete this form with details of the client/patient
The investigator site will contact the owner as screening slots become available should the patient meet the inclusion criteria for the study. Study enrollment may be staggered at each investigation site.
The HALT HCM Study: Addressing Hypertrophic Cardiomyopathy in Cats
The HALT study is a multi-site, blinded, randomized, placebo-controlled clinical field study to provide substantial evidence of effectiveness of a disease modifying drug intervention in the management of ventricular hypertrophy in cats with subclinical HCM. The study will be conducted at multiple clinical sites that are experienced in treating cats with HCM. The study will consist of up to a 14-dayscreening period, followed by a 12-month once-weekly dosing period, with five post-enrollment study visits.
How to Refer a Patient to the HALT Study:
Click below to visit HCMincats.com
Select the investigation site most local to you
Select the veterinarian form
Complete this form with details of the client/patient
The investigator site will contact the owner as screening slots become available should the patient meet the inclusion criteria for the study. Study enrollment may be staggered at each investigation site.
